Recurrent Disease Not Yet Recruiting Phase 2 Trials for Anlotinib (DB11885)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03591666A Study of Anlotinib in Recurrent/Metastatic Head and Neck AdenocarcinomasTreatment